CurrentCignaPolicy N/A

Migraine - Qulipta (atogepant) Prior Authorization Policy

Defines Cigna's prior authorization criteria and coverage stance for Qulipta (atogepant) for migraine prevention in adults under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyMigraine - Qulipta (atogepant) Prior Authorization Policy

Policy CodePolicy N/A

Change TypeMaterial revisions (coverage expansionstep therapy removedclarifications)

Effective DateN/A

Next Review Date02/26/2025

Key ActionSubmit prior authorization demonstrating patient is ≥18 years old with ≥4 migraine headache days/month and required documentation for approval.

SourceLink

POLICY UPDATE CHANGES

Qulipta is indicated for both episodic and chronic migraine prevention; approval criterion changed to require ≥ 4 migraine headache days per month (removed upper bound of <15).

Removed requirement that patients try at least two standard prophylactic pharmacologic therapies from different classes prior to Qulipta.

Concurrent use of Qulipta with another CGRP inhibitor for migraine prevention is considered experimental and not covered.

≥4required migraine headache days per month for approval

1 yeartypical approval duration

Adults ≥18age requirement

Concurrent CGRPnot covered

AHS 2024guidance

Coverage Criteria for Qulipta (atogepant)

Migraine Headache Prevention

Covered when ALL of the following are met:

FDA-Approved Indication - Migraine Headache Prevention: A) Patient is ≥ 18 years of age; AND B) Patient has ≥ 4 migraine headache days per month (prior to initiating a migraine-preventive medication); AND C) If the patient is currently taking Qulipta, patient has had a significant clinical benefit from the medication as determined by the prescriber.≥ 4 migraine headache days/month

Approve for 1 year when all conditions are met. Examples of significant clinical benefit include reduction in overall migraine days per month or reduction in number of severe migraine days per month from the time Qulipta was initiated.

Requests for the concurrent use of Qulipta (atogepant) with another calcitonin gene-related peptide (CGRP) inhibitor prescribed for migraine headache prevention are considered experimental, investigational, or unproven and are not covered. The policy specifically identifies CGRP agents used for migraine prevention (Aimovig, Ajovy, Emgality, Vyepti, Nurtec ODT, and Qulipta) and notes that injectable agents have not been studied in combination with another CGRP-targeting therapy.

Use of Qulipta for any indication other than the FDA-approved migraine prevention indication is considered experimental, investigational, or unproven and is not covered by this policy.

Policy Summary

PayerCigna

PolicyMigraine - Qulipta (atogepant) Prior Authorization Policy

Policy CodePolicy N/A

Change TypeMaterial revisions (coverage expansionstep therapy removedclarifications)

Effective DateN/A

Next Review Date02/26/2025

Key ActionSubmit prior authorization demonstrating patient is ≥18 years old with ≥4 migraine headache days/month and required documentation for approval.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior Authorization is required for Qulipta (atogepant). Approvals are provided for 1 year when FDA-approved indication criteria are met.

Applies to Qulipta (atogepant) prescription benefit
Approval duration: 1 year when criteria met

Step Therapy

Step Therapy Removed

Step therapy requirement has been removed. CGRP-targeting therapies (including oral gepants and injectable monoclonal antibodies) may be considered as first-line preventive therapy for migraine, consistent with AHS guidance; a trial of two standard prophylactic therapies is no longer required.

Reflects AHS 2024 position: CGRP therapies may be first-line
No requirement to fail two standard prophylactic pharmacologic therapies

Documentation Required

Documentation Required for Approval and Continuation

Required documentation for approval and continuation requests must be provided by the prescriber.

Patient age (must be ≥ 18 years for FDA-approved indication)
Baseline migraine frequency: documentation showing ≥ 4 migraine headache days per month prior to initiating preventive therapy
For continuation/renewal: documentation of significant clinical benefit as determined by the prescriber (examples include reduction in overall migraine days per month or reduction in number of severe migraine days per month since Qulipta initiation)

Denial Risk

Concurrent CGRP Therapy — Denial Risk

Concurrent use of Qulipta with another CGRP-pathway inhibitor for migraine prevention is considered experimental/investigational and is not covered.

Concurrent prescribing with Aimovig, Ajovy, Emgality, Vyepti, Nurtec ODT, or another CGRP inhibitor for migraine prevention will be considered investigational and may be denied
Clinical trials did not permit concomitant use of agents acting on the CGRP pathway for prevention

OpenPayer

Migraine - Qulipta (atogepant) Prior Authorization Policy

Coverage Criteria for Qulipta (atogepant)

Key Numeric and Coding Thresholds

Provider Actions, Prior Authorization, and Documentation

Background and Clinical Context

Definitions